Study type

Study topic

Disease /health condition
Human medicinal product

Study type

Non-interventional study

Scope of the study

Drug utilisation
Effectiveness study (incl. comparative)
Safety study (incl. comparative)

Data collection methods

Secondary use of data
Non-interventional study

Non-interventional study design

Case-only
Cohort
Study drug and medical condition

Name of medicine

AVASTIN
MVASI
ZIRABEV
ABEVMY
AYBINTIO
VEGZELMA
ALYMSYS

Study drug International non-proprietary name (INN) or common name

BEVACIZUMAB

Anatomical Therapeutic Chemical (ATC) code

(L01FG01) bevacizumab
bevacizumab

Medical condition to be studied

Hereditary haemorrhagic telangiectasia
Population studied

Short description of the study population

The study population consists of a subset of patients from the CIROCO database who meet specific inclusion criteria.
All included individuals are adults aged 18 years or older, diagnosed with hereditary hemorrhagic telangiectasia (HHT, or Rendu-Osler disease), and have received systemic bevacizumab exclusively as part of routine clinical care for HHT-related manifestations.
Patients treated with bevacizumab for oncological indications or those who received the drug solely within the framework of a clinical trial were excluded from the data extraction and therefore from the analysis.
Only patients followed and treated in France were considered, and all individuals included in the study have not objected to the use of their anonymised health data in accordance with applicable data protection regulations.

Age groups

Adult and elderly population (≥18 years)
Adults (18 to < 65 years)
Adults (18 to < 46 years)
Adults (46 to < 65 years)
Elderly (≥ 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Estimated number of subjects

237